.png)
.png)
First-line, metastatic or recurrent non-small cell lung cancer (nsclc) with no egfr or alk genomic aberrations
Patients with PD-L1 <1% NSCLC remain at a high risk of death in the real world setting1,2†
†OS rates at 5 years were 11% and 25% for PD-L1 <1% and PD-L1 ≥50%, respectively (p-values not evaluated, descriptive analysis); data from a real-world retrospective study of patients with stage III–IV NSCLC treated with first-line anti-PD-(L)1 therapy + chemotherapy (Flatiron Health Oncology Database)1,2
Real-world retrospective study: 5-year OS rates with first-line anti-PD-(L)1 therapy + chemotherapy in patients with stage III–IV NSCLC (Flatiron Health Oncology Database; January 2011 to March 2022)2*
*p-value not evaluated; 5-year OS in patients with PD-L1 1–49% (n=3256) was 15% (descriptive analysis).2 Retrospective, real-world observational studies are subject to inherent limitations, including potential selection bias, incomplete documentation and variability in clinical practice, and are not intended for direct comparison with clinical trials; causality cannot be established based on this dataset as no statistical testing was performed. OPDIVO + YERVOY was not included in this analysis because the study was initiated before these treatments became available.1
Adapted from Waterhouse et al. 2025 (AACR presentation).2
NSCLC = non-small cell lung cancer; OS = overall survival; PD-(L)1 = programmed cell death receptor-1/programmed death-ligand 1; PD-L1 = programmed death-ligand 1; R/M = recurrent or metastatic.
1.Waterhouse et al. Lung Cancer 2021;156:41–9. 2. Waterhouse et al. Five-year real-world survival outcomes of patients with metastatic non-small cell lung cancer receiving first-line immunotherapy-based regimens. Poster presentation at AACR 2025. Poster number 5946.
OPDIVO + YERVOY with chemotherapy is the only dual IO-based regimen in Australia for R/M NSCLC‡ that combines a PD-1 inhibitor and a CTLA-4 inhibitor1–3†
‡with no EGFR or ALK genomic aberrations †Mechanism of action does not necessarily predict clinical effect.
*Mechanism of action findings shown here are based on in vitro laboratory data.1,2,4–8 These results may not reflect clinical efficacy or safety and should be interpreted in that context.
CTLA-4 = cytotoxic T-lymphocyte-associated protein 4; IO = immuno-oncology; NSCLC = non-small cell lung cancer; PD-1 = programmed cell death receptor-1; R/M = recurrent or metastatic; Treg = regulatory T cells.
1. YERVOY® (ipilimumab) Approved Product Information (https://rss.medsinfo.com.au/bq/pi.cfm?product=bqpyervo). 2. OPDIVO® (nivolumab) Approved Product Information (https://rss.medsinfo.com.au/bq/pi.cfm?product=bqpopdiv). 3. Therapeutic Goods Administration (TGA). Australian Register of Therapeutic Goods (ARTG). Available at: www.tga.gov.au/resources/artg. Accessed March 2026. 4. Heinhuis et al. Ann Oncol 2019;30:219–35. 5. Wang et al. Cancer Immunol Res 2014;2:846–56. 6. Brahmer et al. J Clin Oncol 2010;28:3167–75. 7. Felix et al. Oncoimmunology 2016;5(7):1136045. 8. Pico de Coaña et al. Oncotarget 2017;8:21539–53.
OPDIVO and YERVOY are PBS listed. Please refer to www.pbs.gov.au for full authority information.
Before prescribing, please review the full Product Information and boxed warning for OPDIVO (click HERE) and YERVOY (click HERE).
7356-AU-2600027. April 2026.
OPDIVO® and YERVOY® are registered trademarks of Bristol-Myers Squibb Company. BMS Medical Information: 1800 067 567.
